MedKoo Biosciences

About us  |  Services  |  Products  |  News  |  Careers  |  Contact us

 

 

 


 

Back to products

 

 Browse products

Approved anticancer agents

Anticancer agents in trials

Anticancer agents in preclinical trials

Anticancer molecular libraries

 


Other drug agents

Drug intermediates

Bio-reagents and biochemicals

 

 

 

 

 

 

 

 

MedKoo product information:

  

 JNJ-28312141

   

Description of  JNJ-28312141: JNJ-28312141 is an orally active CSF1R inhibitor (Colony-stimulating factor-1 receptor, CRF1R) and also a FLT3 inhibitor. CSF1R  is expressed by many tumors and is a growth factor for macrophages and mediates osteoclast differentiation.  JNJ-28312141 represents a new agent with potential therapeutic activity in acute myeloid leukemia and in settings where CSF-1-dependent macrophages and osteoclasts contribute to tumor growth and skeletal events.

  

Current developer:  Johnson & Johnson.

   

MedKoo Cat#:  406201

Name:  JNJ-28312141

CAS#: 885692-52-4

  

Synonym:  JNJ-28312141; JNJ28312141; JNJ 28312141.

   

IUPAC/Chemical name: 

4-cyano-N-(5-(1-(2-(dimethylamino)acetyl)piperidin-4-yl)-2',3',4',5'-tetrahydro-[1,1'-biphenyl]-2-yl)-1H-imidazole-2-carboxamide

 

Chemical structure

Theoretical analysis

 

JNJ-28312141 structure

 

 

MedKoo Cat#:  406201
Name:  JNJ-28312141
CAS#: 885692-52-4

Chemical Formula: C26H32N6O2
Exact Mass: 460.25867
Molecular Weight: 460.57
Elemental Analysis: C, 67.80; H, 7.00; N, 18.25; O, 6.95

 

 

   

Availability and price:

 

This agent is  available through  custom synthesis.

   

To inquire quotation and lead time or to ask questions, please send email to sales@medkoo.com to describe your needs. A representative will respond your email shortly. We offer big discount for orders of bulk quantities.

 

  

Information about this agent

  

 

 

References

1: Illig CR, Manthey CL, Wall MJ, Meegalla SK, Chen J, Wilson KJ, Ballentine SK,  Desjarlais RL, Schubert C, Crysler CS, Chen Y, Molloy CJ, Chaikin MA, Donatelli RR, Yurkow E, Zhou Z, Player MR, Tomczuk BE. Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]pheny l]-1H-imidazole-2-carboxamide (JNJ-28312141). J Med Chem. 2011 Nov
24;54(22):7860-83. doi: 10.1021/jm200900q. Epub 2011 Oct 31. PubMed PMID: 22039836.


2: Manthey CL, Johnson DL, Illig CR, Tuman RW, Zhou Z, Baker JF, Chaikin MA, Donatelli RR, Franks CF, Zeng L, Crysler C, Chen Y, Yurkow EJ, Boczon L, Meegalla SK, Wilson KJ, Wall MJ, Chen J, Ballentine SK, Ott H, Baumann C, Lawrence D, Tomczuk BE, Molloy CJ. JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol Cancer Ther. 2009 Nov;8(11):3151-61. doi: 10.1158/1535-7163.MCT-09-0255. Epub 2009 Nov 3. PubMed PMID: 19887542.

   

 

 

Contact MedKoo:

Email: sales@medkoo.com

 

(Keyword; CAS#; MedKoo Cat#)

 

 

 

 

 

 

 

About us  |  Services  |  Products  |  News  |  Careers  |  Contact us

MedKoo Biosciences. All Rights Reserved